PsychedelicNewsBreaks

WednesdayMar 02, 2022 3:04 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing for Adoption of and Wider Access to Psychedelic-Based Treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recognizes the opportunity within the mental health treatment space and acknowledges the underlying issues affecting people living with these conditions, especially in the United States. Here, over 51.5 million people have experienced a mental health condition, with figures rising because of the pandemic. “As a leader in new medicines and treatments for the modern world, the company is pushing for psychedelic-based treatment adoptions and access to an even wider pool of individuals who could benefit significantly from these treatments,” a recent article reads. In acknowledging the lack of access…

Continue Reading

WednesdayMar 02, 2022 11:14 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Oppenheimer Annual Healthcare Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its Chief Executive Officer Doug Drysdale will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference. Drysdale’s presentation is slated to begin at 8:40 a.m. ET on Wednesday, March 16, 2022. Interested parties should visit https://ibn.fm/4Yog7 to register for the event and access the webcast. An archived version of the webcast will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/JiX1x About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working…

Continue Reading

TuesdayMar 01, 2022 12:25 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Dr. Matthew Johnson of Johns Hopkins University, a leading researcher of drug and substance abuse, will serve as the lead investigator for the multisite study. “The data from John Hopkins University’s ongoing…

Continue Reading

FridayFeb 25, 2022 1:11 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Feasibility Study to Potentially Open New Frontiers of Understanding Psychedelics

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its receipt of approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow. Enrollment for the study is set to begin early this year. The feasibility study is designed to utilize Kernel’s Flow technology to evaluate ketamine’s psychedelic effect on the cerebral cortex, potentially providing crucial information that may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after…

Continue Reading

FridayFeb 25, 2022 12:07 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a life sciences holding company dedicated to building a portfolio of assets and biotech solutions. The company has announced its entry into a firm agreement in connection with the sale of its former Cobourg, Ontario-based cannabis processing facility and the 64.43-acre property on which the facility is located (the “transaction”). In consideration of the purchase of the facility, the purchaser has agreed to pay a cash sum of CAD$16,500,000, including a deposit of CAD$660,000 (the “deposit”). FSD Pharma received the deposit on Feb. 24, 2022, and the transaction, which is subject…

Continue Reading

FridayFeb 25, 2022 11:49 am

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Ketamine Clinics Improving Accessibility and Reach, Helping Greatest Number of Patients

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is working to make psychedelic-based treatments more accessible and affordable by leveraging its growing chain of clinics in the United States. In 2021, Delic completed the acquisitions of Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers (“KWC”). These acquisitions brought the number of operational wellness clinics under the Delic umbrella to 12. “According to Delic, these clinics are strategically located in secondary cities to improve accessibility and reach as well as help the greatest number of patients. Still, the company plans to serve even more people with the opening…

Continue Reading

FridayFeb 18, 2022 1:42 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Hails Potential of Promising Psychedelic Medicines

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that psychedelic medicine (ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings…” Of the respondents, 18%…

Continue Reading

FridayFeb 18, 2022 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders; the milestone was identified as Year 2 Q2 (iii). According to the transaction agreement, 17,239.5 Cybin class B common shares will be issued to Adelia shareholders when relevant milestones have been met; the class B Shares will be exchangeable for common shares in the capital of Cybin at an exchange rate of 10 to 1. Adelia is working on developing medicinal psychedelics with improved…

Continue Reading

WednesdayFeb 16, 2022 1:27 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough…

Continue Reading

WednesdayFeb 16, 2022 11:36 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the Aegis Virtual Conference. The event will span three days, from Feb 23-25, 2022, with Drysdale’s presentation scheduled to begin at 2 p.m. ET on Thursday, Feb. 24. Interested parties should visit https://ibn.fm/eqPBg to listen to the event and access the webcast. An archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/PrtCB About Cybin Inc. Cybin is a leading ethical…

Continue Reading